Freethemice, I find your remarks intriguing. Accelerated Approval received for second-line NSCLC would allow oncologists to use bavi for first-line NSCLC.
According to the quote below the estimated therapeutic market value for treating NSCLC would project to $5.4 billion for 2012.
“GlobalData estimates that the global NSCLC therapeutics market was valued at $4.5 billion in 2010 and is forecast to grow at a compound annual growth rate (CAGR) of 9.7% for the next eight years, to reach $9.5 billion by 2018.” http://www.bizjournals.com/prnewswire/press_releases/2011/10/25/SP92803
When I think about therapeutic revenues for just one indication (NSCLC) running to $5 billion, and knowing breast cancer and colorectal cancer are even larger markets it’s easy to see how a safe and efficacious broad-spectrum targeting mAb like bavituximab could be worth many billions of dollars to Peregrine as indications are added to the label.
Peregrine is already running trials and ISTs in: NSCLC (3 trials), Pancreatic cancer, Liver cancer, Prostate cancer, and Breast cancer.
We have some super excellent top-line data in now from the second-line NSCLC trial which could be the tipping point indication for bavi, if it receives the FDA Accelerated Approval.
News 
Market Data 
Discover 
